Pay in 4 interest-free payments of $6.68 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Since PBMs emerged decades ago to help plans manage prescriptions, rebates and discounts, they evolved into powerful intermediaries that influence almost every aspect of the drug benefit
In many cases, a provider may consider changing the route or protocol if clinically appropriate
About 12,000 people starting GLP-1 drugs were compared against roughly 15,200 starting SGLT-2 inhibitors, and a separate group of about 12,000 GLP-1 starters was compared against 11,233 starting DPP-4 inhibitors
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial
US$ 21.89
US$ 29.73
US$ 29.83
US$ 24.96
US$ 23.30
